HK1259545A1 - Combination of bcl-2 inhibitor and mek inhibitor for the treatment of cancer - Google Patents
Combination of bcl-2 inhibitor and mek inhibitor for the treatment of cancerInfo
- Publication number
- HK1259545A1 HK1259545A1 HK19100995.4A HK19100995A HK1259545A1 HK 1259545 A1 HK1259545 A1 HK 1259545A1 HK 19100995 A HK19100995 A HK 19100995A HK 1259545 A1 HK1259545 A1 HK 1259545A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- inhibitor
- bcl
- cancer
- treatment
- combination
- Prior art date
Links
- 239000012664 BCL-2-inhibitor Substances 0.000 title 1
- 229940123711 Bcl2 inhibitor Drugs 0.000 title 1
- 229940124647 MEK inhibitor Drugs 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562250231P | 2015-11-03 | 2015-11-03 | |
| US201562263082P | 2015-12-04 | 2015-12-04 | |
| PCT/US2016/060271 WO2017079399A1 (en) | 2015-11-03 | 2016-11-03 | Combination of bcl-2 inhibitor and mek inhibitor for the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1259545A1 true HK1259545A1 (en) | 2019-11-29 |
Family
ID=57471995
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK19100995.4A HK1259545A1 (en) | 2015-11-03 | 2019-01-21 | Combination of bcl-2 inhibitor and mek inhibitor for the treatment of cancer |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US10959993B2 (en) |
| EP (1) | EP3370775B1 (en) |
| JP (1) | JP6724136B2 (en) |
| KR (1) | KR102124715B1 (en) |
| CN (1) | CN108601839B (en) |
| AU (1) | AU2016349279A1 (en) |
| BR (1) | BR112018008882A8 (en) |
| CA (1) | CA3001880C (en) |
| HK (1) | HK1259545A1 (en) |
| IL (1) | IL258741B (en) |
| MA (1) | MA43170A (en) |
| MX (1) | MX2018005233A (en) |
| WO (1) | WO2017079399A1 (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014039855A1 (en) * | 2012-09-07 | 2014-03-13 | Genentech, Inc. | Combination therapy of a type ii anti-cd20 antibody with a selective bcl-2 inhibitor |
| GB201809746D0 (en) * | 2018-06-14 | 2018-08-01 | Berlin Chemie Ag | Pharmaceutical combinations |
| TW202023568A (en) * | 2018-07-30 | 2020-07-01 | 瑞典商阿斯特捷利康公司 | Combination therapy for treating cancer |
| AU2019359872A1 (en) * | 2018-10-16 | 2021-05-27 | The Johns Hopkins University | Compositions and methods for treating vascular Ehlers Danlos Syndrome and associated disorders |
| WO2020181219A1 (en) * | 2019-03-06 | 2020-09-10 | The Regents Of The University Of Colorado, A Body Corporate | Methods of detecting and treating venetoclax-resistant acute myeloid leukemia |
| JP2022533009A (en) * | 2019-04-29 | 2022-07-21 | イミュノジェン， インコーポレイテッド | Therapeutic combination including anti-CD123 immune complex |
| WO2020247275A2 (en) * | 2019-06-03 | 2020-12-10 | Sanford Burnham Prebys Medical Discovery Institute | Uses of synthetic lethal partners for treatment of cancer |
| US11957701B2 (en) | 2020-07-17 | 2024-04-16 | Delta-Fly Pharma, Inc. | Therapy and new therapeutic agent for blood cancer |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5129143B2 (en) | 2005-10-07 | 2013-01-23 | エグゼリクシス， インコーポレイテッド | MEK inhibitor and method of use thereof |
| JP2011519868A (en) * | 2008-05-05 | 2011-07-14 | シェーリング コーポレイション | Continuous administration of chemotherapeutic agents to treat cancer |
| WO2009151569A2 (en) * | 2008-06-09 | 2009-12-17 | Combinatorx, Incorporated | Beta adrenergic receptor agonists for the treatment of b-cell proliferative disorders |
| US8546399B2 (en) | 2009-05-26 | 2013-10-01 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
| UA113500C2 (en) | 2010-10-29 | 2017-02-10 | MEL EXTRUSION SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT | |
| RU2598345C2 (en) | 2010-10-29 | 2016-09-20 | Эббви Инк. | Solid dispersions containing agents causing apoptosis |
| BR112013012740A2 (en) | 2010-11-23 | 2016-09-13 | Abbvie Inc | salts and crystalline forms of an apoptosis inducing agent |
| PT2642999T (en) | 2010-11-23 | 2017-01-05 | Abbvie Ireland Unlimited Co | Methods of treatment using selective bcl-2 inhibitors |
| AU2012333092B2 (en) * | 2011-08-31 | 2016-04-21 | Novartis Ag | Synergistic combinations of PI3K- and MEK-inhibitors |
| CA2879252C (en) | 2012-08-17 | 2017-10-10 | F. Hoffmann-La Roche Ag | Combination therapies for melanoma comprising administering cobimetinib and vemurafinib |
| WO2014039855A1 (en) | 2012-09-07 | 2014-03-13 | Genentech, Inc. | Combination therapy of a type ii anti-cd20 antibody with a selective bcl-2 inhibitor |
| WO2015051252A1 (en) | 2013-10-03 | 2015-04-09 | Duke University | Compositions and methods for treating cancer with jak2 activity |
-
2016
- 2016-11-03 BR BR112018008882A patent/BR112018008882A8/en not_active IP Right Cessation
- 2016-11-03 MX MX2018005233A patent/MX2018005233A/en unknown
- 2016-11-03 CA CA3001880A patent/CA3001880C/en active Active
- 2016-11-03 EP EP16805576.2A patent/EP3370775B1/en active Active
- 2016-11-03 MA MA043170A patent/MA43170A/en unknown
- 2016-11-03 CN CN201680077558.7A patent/CN108601839B/en active Active
- 2016-11-03 WO PCT/US2016/060271 patent/WO2017079399A1/en active Application Filing
- 2016-11-03 JP JP2018522692A patent/JP6724136B2/en active Active
- 2016-11-03 KR KR1020187012054A patent/KR102124715B1/en active IP Right Grant
- 2016-11-03 US US15/767,914 patent/US10959993B2/en active Active
- 2016-11-03 AU AU2016349279A patent/AU2016349279A1/en not_active Abandoned
-
2018
- 2018-04-16 IL IL258741A patent/IL258741B/en unknown
-
2019
- 2019-01-21 HK HK19100995.4A patent/HK1259545A1/en unknown
-
2021
- 2021-02-18 US US17/178,609 patent/US20210169865A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2017079399A1 (en) | 2017-05-11 |
| CA3001880C (en) | 2021-08-17 |
| MA43170A (en) | 2018-09-12 |
| BR112018008882A8 (en) | 2019-02-26 |
| US10959993B2 (en) | 2021-03-30 |
| CA3001880A1 (en) | 2017-05-11 |
| AU2016349279A1 (en) | 2018-05-10 |
| BR112018008882A2 (en) | 2018-11-06 |
| IL258741A (en) | 2018-06-28 |
| US20210169865A1 (en) | 2021-06-10 |
| JP2018534298A (en) | 2018-11-22 |
| CN108601839B (en) | 2021-10-26 |
| CN108601839A (en) | 2018-09-28 |
| MX2018005233A (en) | 2019-04-29 |
| JP6724136B2 (en) | 2020-07-15 |
| KR20180054852A (en) | 2018-05-24 |
| KR102124715B1 (en) | 2020-06-18 |
| US20180303815A1 (en) | 2018-10-25 |
| IL258741B (en) | 2021-08-31 |
| EP3370775B1 (en) | 2023-04-19 |
| EP3370775A1 (en) | 2018-09-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL272948A (en) | Enpp1 inhibitors and their use for the treatment of cancer | |
| HK1252873A1 (en) | Vaccines for treatment and prevention of cancer | |
| ZA201607415B (en) | Antibody-drug-conjugate and its use for the treatment of cancer | |
| HK1247129A1 (en) | Combination therapy for the treatment of cancer | |
| HK1259545A1 (en) | Combination of bcl-2 inhibitor and mek inhibitor for the treatment of cancer | |
| HK1251475A1 (en) | Combination therapy for the treatment of cancer | |
| ZA201900960B (en) | Methods and compositions for the treatment of cancer | |
| HRP20190888T8 (en) | Igf-1r antibody-drug-conjugate and its use for the treatment of cancer | |
| PL3558280T3 (en) | Migraine prevention and treatment | |
| IL280587B (en) | Flurocytidine derivatives and its composition for the treatment of cancer | |
| EP3185910A4 (en) | Methods and compositions for the treatment of cancer | |
| IL255169A0 (en) | Anti-fugetactic agent and immunotherapy agent combination therapy and compositions for the treatment of cancer | |
| IL272147A (en) | Methods and compositions for the treatment of cancer | |
| IL269121A (en) | Usl-311 for use in the treatment of cancer | |
| IL252493A0 (en) | Compounds for use in the prevention or treatment of cancer | |
| ZA201904626B (en) | Cancer treatment method and composition | |
| EP3365013A4 (en) | Methods and related compositions for the treatment of cancer | |
| GB201518489D0 (en) | Methods for the treatment and prevention of ebola | |
| GB201403086D0 (en) | Selection of virus and agent useful in the treatment of cancer | |
| GB201418640D0 (en) | Agents and methods for treatment of cancer |